Impact of the everolimus-eluting stent on stent thrombosis: A meta-analysis of 13 randomized trials

Usman Baber, Roxana Mehran, Samin K. Sharma, Somjot Brar, Jennifer Yu, Jung Won Suh, Hyo Soo Kim, Seung Jung Park, Adnan Kastrati, Antoinette De Waha, Prakash Krishnan, Pedro Moreno, Joseph Sweeny, Michael C. Kim, Javed Suleman, Robert Pyo, Jose M. Wiley, Jason Kovacic, Annapoorna S. Kini, George D. Dangas

Research output: Contribution to journalArticle

220 Citations (Scopus)

Abstract

Objectives: We evaluated the impact of the everolimus-eluting stent (EES) on the frequency of stent thrombosis (ST), target vessel revascularization (TVR), myocardial infarction (MI), and cardiac death in randomized controlled trials comparing the EES to noneverolimus-eluting drug-eluting stents (EE-DES). Background: Whether or not the unique properties of the EES translate into reductions in ST remains unknown. Methods: We searched MEDLINE, Scopus, the Cochrane Library, and Internet sources for articles comparing outcomes between EES and nonEE-DES without language or date restriction. Randomized controlled trials reporting the frequency of ST were included. Variables relating to patient and study characteristics and clinical endpoints were extracted. Results: We identified 13 randomized trials (n = 17,101) with a weighted mean follow-up of 21.7 months. Compared with nonEE-DES, the EES significantly reduced ST (relative risk [RR]: 0.55; 95% confidence interval [CI]: 0.38 to 0.78; p = 0.001), TVR (RR: 0.77; 95% CI: 0.64 to 0.92; p = 0.004), and MI (RR: 0.78; 95% CI: 0.64 to 0.96; p = 0.02). There was no difference in cardiac mortality between the groups (RR: 0.92; 95% CI: 0.74 to 1.16; p = 0.38). The treatment effect was consistent by different follow-up times and duration of clopidogrel use. The treatment effects increased with higher baseline risks of the respective control groups with the strongest correlation observed for ST (R 2 = 0.89, p < 0.001). Conclusions: Intracoronary implantation of the EES is associated with highly significant reductions in ST with concordant reductions in TVR and MI compared to nonEE-DES. Whether these effects apply to different patient subgroups and DES types merits further investigation.

Original languageEnglish (US)
Pages (from-to)1569-1577
Number of pages9
JournalJournal of the American College of Cardiology
Volume58
Issue number15
DOIs
StatePublished - Oct 4 2011
Externally publishedYes

Fingerprint

Stents
Meta-Analysis
Thrombosis
Confidence Intervals
clopidogrel
Myocardial Infarction
Everolimus
Randomized Controlled Trials
Drug-Eluting Stents
MEDLINE
Internet
Libraries
Language
Control Groups
Mortality

Keywords

  • drug-eluting stent
  • everolimus-eluting
  • stent thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of the everolimus-eluting stent on stent thrombosis : A meta-analysis of 13 randomized trials. / Baber, Usman; Mehran, Roxana; Sharma, Samin K.; Brar, Somjot; Yu, Jennifer; Suh, Jung Won; Kim, Hyo Soo; Park, Seung Jung; Kastrati, Adnan; De Waha, Antoinette; Krishnan, Prakash; Moreno, Pedro; Sweeny, Joseph; Kim, Michael C.; Suleman, Javed; Pyo, Robert; Wiley, Jose M.; Kovacic, Jason; Kini, Annapoorna S.; Dangas, George D.

In: Journal of the American College of Cardiology, Vol. 58, No. 15, 04.10.2011, p. 1569-1577.

Research output: Contribution to journalArticle

Baber, U, Mehran, R, Sharma, SK, Brar, S, Yu, J, Suh, JW, Kim, HS, Park, SJ, Kastrati, A, De Waha, A, Krishnan, P, Moreno, P, Sweeny, J, Kim, MC, Suleman, J, Pyo, R, Wiley, JM, Kovacic, J, Kini, AS & Dangas, GD 2011, 'Impact of the everolimus-eluting stent on stent thrombosis: A meta-analysis of 13 randomized trials', Journal of the American College of Cardiology, vol. 58, no. 15, pp. 1569-1577. https://doi.org/10.1016/j.jacc.2011.06.049
Baber, Usman ; Mehran, Roxana ; Sharma, Samin K. ; Brar, Somjot ; Yu, Jennifer ; Suh, Jung Won ; Kim, Hyo Soo ; Park, Seung Jung ; Kastrati, Adnan ; De Waha, Antoinette ; Krishnan, Prakash ; Moreno, Pedro ; Sweeny, Joseph ; Kim, Michael C. ; Suleman, Javed ; Pyo, Robert ; Wiley, Jose M. ; Kovacic, Jason ; Kini, Annapoorna S. ; Dangas, George D. / Impact of the everolimus-eluting stent on stent thrombosis : A meta-analysis of 13 randomized trials. In: Journal of the American College of Cardiology. 2011 ; Vol. 58, No. 15. pp. 1569-1577.
@article{34834ca6df514fbfa3502415dcbb09f3,
title = "Impact of the everolimus-eluting stent on stent thrombosis: A meta-analysis of 13 randomized trials",
abstract = "Objectives: We evaluated the impact of the everolimus-eluting stent (EES) on the frequency of stent thrombosis (ST), target vessel revascularization (TVR), myocardial infarction (MI), and cardiac death in randomized controlled trials comparing the EES to noneverolimus-eluting drug-eluting stents (EE-DES). Background: Whether or not the unique properties of the EES translate into reductions in ST remains unknown. Methods: We searched MEDLINE, Scopus, the Cochrane Library, and Internet sources for articles comparing outcomes between EES and nonEE-DES without language or date restriction. Randomized controlled trials reporting the frequency of ST were included. Variables relating to patient and study characteristics and clinical endpoints were extracted. Results: We identified 13 randomized trials (n = 17,101) with a weighted mean follow-up of 21.7 months. Compared with nonEE-DES, the EES significantly reduced ST (relative risk [RR]: 0.55; 95{\%} confidence interval [CI]: 0.38 to 0.78; p = 0.001), TVR (RR: 0.77; 95{\%} CI: 0.64 to 0.92; p = 0.004), and MI (RR: 0.78; 95{\%} CI: 0.64 to 0.96; p = 0.02). There was no difference in cardiac mortality between the groups (RR: 0.92; 95{\%} CI: 0.74 to 1.16; p = 0.38). The treatment effect was consistent by different follow-up times and duration of clopidogrel use. The treatment effects increased with higher baseline risks of the respective control groups with the strongest correlation observed for ST (R 2 = 0.89, p < 0.001). Conclusions: Intracoronary implantation of the EES is associated with highly significant reductions in ST with concordant reductions in TVR and MI compared to nonEE-DES. Whether these effects apply to different patient subgroups and DES types merits further investigation.",
keywords = "drug-eluting stent, everolimus-eluting, stent thrombosis",
author = "Usman Baber and Roxana Mehran and Sharma, {Samin K.} and Somjot Brar and Jennifer Yu and Suh, {Jung Won} and Kim, {Hyo Soo} and Park, {Seung Jung} and Adnan Kastrati and {De Waha}, Antoinette and Prakash Krishnan and Pedro Moreno and Joseph Sweeny and Kim, {Michael C.} and Javed Suleman and Robert Pyo and Wiley, {Jose M.} and Jason Kovacic and Kini, {Annapoorna S.} and Dangas, {George D.}",
year = "2011",
month = "10",
day = "4",
doi = "10.1016/j.jacc.2011.06.049",
language = "English (US)",
volume = "58",
pages = "1569--1577",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "15",

}

TY - JOUR

T1 - Impact of the everolimus-eluting stent on stent thrombosis

T2 - A meta-analysis of 13 randomized trials

AU - Baber, Usman

AU - Mehran, Roxana

AU - Sharma, Samin K.

AU - Brar, Somjot

AU - Yu, Jennifer

AU - Suh, Jung Won

AU - Kim, Hyo Soo

AU - Park, Seung Jung

AU - Kastrati, Adnan

AU - De Waha, Antoinette

AU - Krishnan, Prakash

AU - Moreno, Pedro

AU - Sweeny, Joseph

AU - Kim, Michael C.

AU - Suleman, Javed

AU - Pyo, Robert

AU - Wiley, Jose M.

AU - Kovacic, Jason

AU - Kini, Annapoorna S.

AU - Dangas, George D.

PY - 2011/10/4

Y1 - 2011/10/4

N2 - Objectives: We evaluated the impact of the everolimus-eluting stent (EES) on the frequency of stent thrombosis (ST), target vessel revascularization (TVR), myocardial infarction (MI), and cardiac death in randomized controlled trials comparing the EES to noneverolimus-eluting drug-eluting stents (EE-DES). Background: Whether or not the unique properties of the EES translate into reductions in ST remains unknown. Methods: We searched MEDLINE, Scopus, the Cochrane Library, and Internet sources for articles comparing outcomes between EES and nonEE-DES without language or date restriction. Randomized controlled trials reporting the frequency of ST were included. Variables relating to patient and study characteristics and clinical endpoints were extracted. Results: We identified 13 randomized trials (n = 17,101) with a weighted mean follow-up of 21.7 months. Compared with nonEE-DES, the EES significantly reduced ST (relative risk [RR]: 0.55; 95% confidence interval [CI]: 0.38 to 0.78; p = 0.001), TVR (RR: 0.77; 95% CI: 0.64 to 0.92; p = 0.004), and MI (RR: 0.78; 95% CI: 0.64 to 0.96; p = 0.02). There was no difference in cardiac mortality between the groups (RR: 0.92; 95% CI: 0.74 to 1.16; p = 0.38). The treatment effect was consistent by different follow-up times and duration of clopidogrel use. The treatment effects increased with higher baseline risks of the respective control groups with the strongest correlation observed for ST (R 2 = 0.89, p < 0.001). Conclusions: Intracoronary implantation of the EES is associated with highly significant reductions in ST with concordant reductions in TVR and MI compared to nonEE-DES. Whether these effects apply to different patient subgroups and DES types merits further investigation.

AB - Objectives: We evaluated the impact of the everolimus-eluting stent (EES) on the frequency of stent thrombosis (ST), target vessel revascularization (TVR), myocardial infarction (MI), and cardiac death in randomized controlled trials comparing the EES to noneverolimus-eluting drug-eluting stents (EE-DES). Background: Whether or not the unique properties of the EES translate into reductions in ST remains unknown. Methods: We searched MEDLINE, Scopus, the Cochrane Library, and Internet sources for articles comparing outcomes between EES and nonEE-DES without language or date restriction. Randomized controlled trials reporting the frequency of ST were included. Variables relating to patient and study characteristics and clinical endpoints were extracted. Results: We identified 13 randomized trials (n = 17,101) with a weighted mean follow-up of 21.7 months. Compared with nonEE-DES, the EES significantly reduced ST (relative risk [RR]: 0.55; 95% confidence interval [CI]: 0.38 to 0.78; p = 0.001), TVR (RR: 0.77; 95% CI: 0.64 to 0.92; p = 0.004), and MI (RR: 0.78; 95% CI: 0.64 to 0.96; p = 0.02). There was no difference in cardiac mortality between the groups (RR: 0.92; 95% CI: 0.74 to 1.16; p = 0.38). The treatment effect was consistent by different follow-up times and duration of clopidogrel use. The treatment effects increased with higher baseline risks of the respective control groups with the strongest correlation observed for ST (R 2 = 0.89, p < 0.001). Conclusions: Intracoronary implantation of the EES is associated with highly significant reductions in ST with concordant reductions in TVR and MI compared to nonEE-DES. Whether these effects apply to different patient subgroups and DES types merits further investigation.

KW - drug-eluting stent

KW - everolimus-eluting

KW - stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=80053337086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053337086&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2011.06.049

DO - 10.1016/j.jacc.2011.06.049

M3 - Article

C2 - 21924575

AN - SCOPUS:80053337086

VL - 58

SP - 1569

EP - 1577

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 15

ER -